Predictors of acute mortality in patients with cardiogenic shock treated with Impella device
- Conditions
- Cardiogenic shock
- Registration Number
- JPRN-UMIN000040460
- Lead Sponsor
- ippon Medical School Hospital
- Brief Summary
Sixty-seven with cardiogenic shock with Impella were evaluated. The 30-day mortality rate and rate of requiring escalation therapy were 24% and 18%, respectively. The P terminal force in lead V1 (PTF) was significantly higher in the deteriorated group than in the recovered group (0.052+/-0.032 vs. 0.022+/-0.010 mm*s, respectively; p<0.001). On ROC analysis, PTF>0.035 mm*s identified the deteriorated group with a sensitivity of 73% and specificity of 96% (AUC=0.93, p<0.001).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 67
Not provided
Exclusion criteria included the evidence of anoxic brain injury before the implantation, unwitnessed out of hospital cardiac arrest or any cardiac arrest in which ROSC is not achieved in 30 minutes, non-cardiogenic shock (distributive, hypovolemic, or obstructive shock),or severe right ventricular dysfunction.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of this study was defined as all-cause mortality during a 30-day follow-up period after the implantation of Impella device.
- Secondary Outcome Measures
Name Time Method The secondary endpoint was the occurrence of escalated therapy (Impella 5.0 or PCPS) or died.